Sunday, November 25, 2012 6:30:27 AM
Once in the cell, as I have explained in the very first post, Bavi remains bound to the PS located at the inner cell membrane that was involved in providing the inwards traction (see previous post). Bavi is not active in the sense it does something there as long as the cell is undamaged (that is as long as PS is not exposed on the outside of the cell). I called it to be in a cloaked state (for the immune system), call it dormant, call it passively present bound to the inner cell membrane's PS.
Two posts ago I used the sentence "Bavi is dressed, booted and arm for action", meaning that if while it is in it's dormant state bound to the membrane's PS, upon damage of the cell (e.g.: cracks in a cell membrane or other damage involving the membrane that comes into existence) the PS and the attached Bavi will be exposed. As a consequence it's immune system 'suppressor-suppressor' function will immediately be active (the so called masking function). That is where I should have used another word.
The word 'active' seems to be the trigger for your reaction, because I agree that in antibody language it carries other significance, hence my past effort in writing: "exposes behavior that makes us think about it as an active antibody alike substance but it is not an antibody". This expresses that it exposes signs of activity which may not qualify as being the results of the grounds that we normally find at the basis such observed activity (e.g.: as with antibodies).
So while I called the PS+Bavi couple when it becomes exposed outside the cell 'becoming active' maybe i would have better used 'Bavi becoming effective', because Bavi ALREADY being bound to PS makes it immediately effective as the immune system 'suppressor-suppressor' with ZERO latency. It would be even more effective because it's already on the scene compared to Bavi administered during treatment shortly after diagnosis. (Not even sure if there wouldn't be a better word then 'effective' but in English i'll probably won't come up with it).
Now I'll respect that you'll call it nonsense, but I would appreciate you add exactly why. As I said, there where times we tough the atom was a fundamental particle and we had no clues about electrons, protons, neutrons, up/down quarks, etc.
I think I provided an answer to:
I reconfirmed that I don't believe Bavi is an anti-body:
I explained what i think to be plausible theory, without the claim it is exactly that what is going on, for the "Persistent Presence" theory vs the active anti-body theory:
FTM, I respect you and you are a knowledgeable poster, if not the most knowledgeable one. Ask questions as much as you want and I'll try to answer them at the best of my ability. Bavi has prolonged activity/effectiveness or signs that identify as something alike and Thorpe has not given an explanation, neither did anybody else. If you think the MOA anticipates or explains this feel free to point it out. I think it doesn't and therefor think the MOA will at the least have to be updated at some point to include this aspect of Bavi's prolonged 'effect' after it left the body. So all roads are open, but frankly, and you may help me out if you see others, I only see two overall possible concepts: an active antibody-alike theory or a persistent Bavi presence theory.
If you see another that doesn't involve an active antibody alike approach nor rests on the persistent presence of Bavi at some level in our body (not even inside the cell as I think) then pls, I am all ears and open to the wildest theories because looking at all possibilities will some day lead to results. Very possibly if 100 scenarios are advance it will be scenario 101 which nobody ever thought of. I can also understand that you are not into 'theoretical speculation' and the 'if you see...' was not a challenge to drive you in proposing a theory of your own, just a matter of language usage.
All In My Opinion. I am not advising anything, nor accusing anyone.
Recent CDMO News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2024 09:15:31 PM
- Rowley Law PLLC is Investigating Proposed Acquisition of Avid Bioservices, Inc. • PR Newswire (US) • 11/07/2024 10:55:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2024 02:59:47 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2024 02:42:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 02:11:21 AM
- Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction • GlobeNewswire Inc. • 11/06/2024 11:04:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 08:45:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/15/2024 11:40:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 11:38:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 11:38:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 11:37:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/11/2024 12:22:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/11/2024 12:21:22 AM
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference • GlobeNewswire Inc. • 09/12/2024 08:05:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/09/2024 08:43:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:19:30 PM
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 • GlobeNewswire Inc. • 09/09/2024 08:05:31 PM
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM